Call Now! 1-415-956-6062
HOME OVERVIEW HISTORY LOCATIONS PRACTICE AREAS ATTORNEYS CONTACT
ATTORNEYS
  • Kurt R. Karst

    Hyman, Phelps & McNamara, P.C.
    700 13th Street NW
    Suite 1200
    Washington, D.C. 20005, U.S.A.
  • Intellectual Property

    Bio

    Education • J.D., American University Washington College of Law • B.A., Political Science and German, Marquette University Bar Admissions • District of Columbia • Maryland Awards & Recognition • Who's Who Legal Directory, Life Sciences, Regulatory Section, 2015 • Who's Who Legal Directory, Life Sciences, Patent Litigation Section, 2015 Articles / Publications • FDA Amendments Act - HPM Issues Detailed Summary and Analysis, October 2007 • FDA Announces Proposed Regulations to Overhaul and Expand the Availability of Experimental Drugs and to Clarify Permissible Charges to Patients, December 12, 2006 • Rep. Waxman and Sens. Schumer and Clinton Introduce Biogenerics Bill, September 29, 2006 • FDA's Final Compliance Policy Guide for Marketed Unapproved Drugs ─ Is Agency Enforcement at a Crossroads, or Stuck in a Traffic Circle?, August 11, 2006 • New Law Reins in "Authorized Generics" Despite Generic Industry Court Losses, But Leaves Several Ambiguities, June 2006 • District Court Rules on Simvastatin 180-Day Exclusivity, May 5, 2006 • FDA Issues Long-Awaited Prescription Drug Labeling Regulations, January 26, 2006 • FDA's Unauthorized User Fee Money Grab, August 12, 2005 • FDA Draft Guidance on Exploratory IND Studies, April 22, 2005 • FDA Issues Good Review Management Principles and Practices Guidance Document, April 22, 2005 • How FDA's New Labeling Rule Could Preempt State Law • Comments, Pediatric Testing of Prescription Drugs: The Food and Drug Administration's Carrot and Stick for the Pharmaceutical Industry